Sarepta Therapeutics

Yahoo Finance • 13 days ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 14 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 31, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensat... Full story

Yahoo Finance • 20 days ago

Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now. Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley’s 25-percent price... Full story

Yahoo Finance • 20 days ago

The VIX Crashes Out, For Now, on Hope For Peace and Cheaper Oil

Quick Read Arm (ARM) surged 13% after unveiling its AGI CPU for agentic AI workloads, projecting $25B in total revenue and $9 per share in annual earnings within five years with $15B tied to the new chip, while Intel (INTC) rose 3% and AM... Full story

Yahoo Finance • 20 days ago

Sarepta Surges As It Takes On Novartis' $12 Billion Muscular Dystrophy Buyout

Sarepta stock popped Wednesday after the company reported promising results for its gene-silencing tech in two forms of muscular dystrophy. Continue Reading... Full story

Yahoo Finance • 24 days ago

2 Beaten-Down Stocks That Still Aren't Worth Buying

It's often wise to wait until a significant correction before investing in a stock. However, that strategy only works when the company can recover from whatever obstacle led to the sell-off. When that's not the case, investing in a beaten-... Full story

Yahoo Finance • last month

FDA vaccine chief to leave the agency again

[FDA Headquarters] For the second time in less than a year, Vinay Prasad, the head of the U.S. Food and Drug Administration’s vaccines unit, is leaving the agency, according to a statement from the FDA commissioner, Marty Makary. Prasad... Full story

Yahoo Finance • last month

Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics

Company Logo The oligonucleotides market offers opportunities in therapeutic applications, particularly for untreated diseases using ASOs, siRNA, and aptamers, with leaders like Alnylam driving innovation. Growth also spans diagnostics an... Full story

Yahoo Finance • last month

Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the best cheap biotech stocks to buy now. On February 27, Wells Fargo cut the price target on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $38 from $45 while maintaining an Overweight ratin... Full story

Yahoo Finance • last month

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

We came across a bullish thesis on Sarepta Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.'s share was trading at $18.88 as of February 20th. SRPT’s tr... Full story

Yahoo Finance • last month

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta Therapeutics, Inc.(NASDAQ:SRPT) shares are down during Thursday’s premarket session as the company reported its fourth-quarter and full-year 2025 financial results. Over the last year, the company’s stock has plunged from $106.86... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics Inc (SRPT) Q4 2025 Earnings Call Highlights: Strong Financial Position ...

This article first appeared on GuruFocus. Cash and Investments: $954 million at the end of 2025, with an increase of $89 million in the fourth quarter. Net Product Revenue for 2025: $1.86 billion, with $966 million from PMO franchise and... Full story

Yahoo Finance • 2 months ago

Sarepta (SRPT) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Feb. 25, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Douglas IngramChief Commercial Officer — Patrick MossPresident, Head of R&D, Chief Scientific Officer — Dr. Louise Rodino-Kla... Full story

Yahoo Finance • 2 months ago

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and gover... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ...

This article first appeared on GuruFocus. Net Income: $30.8 million for the quarter ended December 31, 2025. Earnings Per Share (EPS): $0.22 per share based on 140.7 million fully diluted weighted average shares outstanding. Revenue: $264... Full story

Yahoo Finance • 2 months ago

Cytokinetics, Incorporated (CYTK): A Bull Case Theory

We came across a bullish thesis on Cytokinetics, Incorporated on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on CYTK. Cytokinetics, Incorporated's share was trading at $65.16 as of February 2nd.Coge... Full story

Yahoo Finance • 4 months ago

6 Stocks That Fell Off Hard in 2025

Some stocks that looked solid in 2024 didn’t make it through 2025 unscathed. Between tariffs, slower growth and changing consumer habits, a few big names took serious hits this year. Here are six companies that started 2025 in decent shap... Full story

Yahoo Finance • 5 months ago

How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management?

Earlier this week, Sarepta Therapeutics received FDA approval to begin dosing non-ambulant Duchenne muscular dystrophy patients in Cohort 8 of the ENDEAVOR study, evaluating an enhanced immunosuppression regimen with Elevidys, and announce... Full story

Yahoo Finance • 5 months ago

Trump Media and 11 More Stocks to Avoid Until 2026

Investors should be extra cautious when thinking about being contrarians and buying losers at the end of any calendar year. Continue Reading View Comments... Full story

Yahoo Finance • 5 months ago

Sarepta gene therapy Elevidys gets FDA Boxed Warning following two patient deaths

[Alphabet letter in word FDA (abbreviation of food and drug administration) on wood background] bankrx * The US FDA has ordered a Boxed Warning be added to the labeling of Sarepta Therapeutics' (SRPT [https://seekingalpha.com/symbol/SRP... Full story